Annual report
7459.TEDINET S100YI1C
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.82T | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥3.67T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥3.56T | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.36T | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.29T | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥53.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥55.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥75.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥65.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥64.6bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥65.1bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥62.0bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥81.8bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥76.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥42.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥41.5bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥38.8bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥29.4bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥53.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥51.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.92T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.82T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.80T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.71T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.71T | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.13T | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.07T | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥795.4bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥757.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥736.6bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥688.1bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥649.1bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥289.1bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥261.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥286.5bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥259.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥260.4bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥46.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥60.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥61.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥9.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥39.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥24.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥29.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥43.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥206.67 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.83 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.82 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.14 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥179.12 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.41 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥3,186.01 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,979.39 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,858.57 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,673.62 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,525.72 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.9% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.4% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.8% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.0% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,024 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 13,061 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 13,075 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 12,795 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 12,801 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥31.2bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥30.4bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥30.3bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥33.0bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥26.6bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue2 (5-year summary) |
| Operating income | ¥17.0bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥19.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥23.2bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥20.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.1bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.2bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.9bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.2bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥23.8bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥16.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥20.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.8bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥371.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥368.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥368.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥355.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥373.6bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥27.7bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥23.7bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥343.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥345.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥345.7bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥333.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥321.0bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥49.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥35.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥77.75 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.58 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.55 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.07 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.99 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥98.81 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.93 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥66 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥62 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,677.78 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,659.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,646.21 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,588.95 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,528.64 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 92.5% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.0% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 215,975,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 219,226,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 221,291,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 225,463,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 186 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 185 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 183 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 173 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 173 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥12m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥110m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥51.8bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | ¥134m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥486m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥1.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | employees | at 2026-03-31 | 796 pure |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥117.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥117.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2026-03-31 | ¥80.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.3bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥6.3bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | employees | at 2026-03-31 | 2363 pure |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.24T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.24T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥283m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2026-03-31 | ¥529.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥26.4bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.7bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥8.8bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | employees | at 2026-03-31 | 9667 pure |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.47T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.46T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.6bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2026-03-31 | ¥1.26T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥24.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥16.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥3.82T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥3.82T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.87T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥53.0bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥148m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥41m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥38.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥50m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥702m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥116.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥116.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2025-03-31 | ¥83.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.19T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.19T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥345m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥503.6bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥28.0bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥8.6bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.37T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.37T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥1.20T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥25.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.68T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥3.67T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.79T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥55.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,157
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)武久 善栄 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)御厨 健太郎 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)今井 仁子 | |
| Audit opinion consolidated (text) | FilingDateInstant | Text · Plus | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)シグニホールディングス株式会社の株式取得により計上されたのれんの合理性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項（企業結合等関係） | |
| Reference2 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（重要な会計上の見積り）(2)のれんの評価」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)医療用医薬品等卸売事業におけるアローアンス計上額の妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)武久 善栄 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)御厨 健太郎 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)今井 仁子 | |
| Audit opinion non consolidated (text) | FilingDateInstant | Text · Plus | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)市場価格のない株式等の評価の適切性 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（重要な会計上の見積り）(2)市場価格のない株式等」 | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 3290921000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 3360008000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 3558732000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 3671328000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 3817354000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 62046000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 65122000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 64570000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 65255000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 75723000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 29423000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 38806000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 41474000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 40279000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 42534000000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 25291000000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 51084000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |